Skip to contentF
Fennec Pharmaceuticals Inc.
F
FENCFennec Pharmaceuticals Inc. Q2 2026 · 10-Q
Revenue$17.87M$17.87M+85.2% vs Q2 2025 Net Income$1.97M$1.97MN/M vs Q2 2025 EPS Diluted$0.05$0.05N/M vs Q2 2025 Operating Income$1,737,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fennec Pharmaceuticals Inc. · CIK 1211583 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin9.7%+38.0 pt vs Q2 2025
Net margin11.0%+43.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end